---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-000005"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T18:11:25.952885+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer; grants 150k stock option

## Summary
- Jennifer Riley appointed Chief Strategy Officer effective Jan 1, 2025; oversees corporate strategy and pipeline planning.
- Base salary $450,000; discretionary annual bonus target up to 40% of base salary.
- Received inducement stock option to purchase 150,000 shares, vesting over 4 years with 12-month cliff.
- Severance includes 9 months base salary (12 months if termination within 6 months after Change in Control) and full option vesting.
- Company advancing AVTX-009 (anti-IL-1β mAb) in LOTUS Phase 2 trial for hidradenitis suppurativa.

## SEC filing metadata
- accession: 0001628280-25-000005
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/0001628280-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/avtx-20250101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-000005
- JSON: https://secwatch.observer/filing/0001628280-25-000005.json
- Plain text: https://secwatch.observer/filing/0001628280-25-000005.txt

## Key facts
- Executive change
  Jennifer Riley was appointed as Chief Strategy Officer at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Strategy Officer
  source text: On January 2, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/0001628280-25-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.